The official ceremony took place at the production site of "GEROPHARM" in Pushkin (Saint Petersburg). According to the document, the cooperation between the two companies will cover the production of genetically engineered human insulin and insulin analogues. JLLC "Nativity" will be the first in Belarus non-state local manufacturer of modular forms that will give the opportunity to optimize the expenditure of budgetary funds in the purchase of foreign insulin producers. The project will improve the treatment of diabetes, to meet the needs of patients in the modern form of insulin, experts said.
"We are glad that the company GEROPHARM, which has a strong expertise and its own technologies in this field, has become a partner of Nativita. The start of insulin production using the technology of the Russian partner and their introduction to the market of Belarus will be the first stage of cooperation. In the future, it is planned to expand the portfolio of drugs for the treatment of diabetes, which will increase the availability of modern therapy for Belarusian patients", - said the Executive Director of "Nativita" Vladimir Sychev.
The GEROPHARM company is the only Russian producer of genetically engineered insulin of the person on the principle of a full cycle (from substance synthesis to a ready dosage form). The company was established in 2001, has two production sites in Moscow and St. Petersburg. The volume of investments in technological innovations and R & d in 2013-2017 exceeded 6 billion Russian rubles.
JLLC "Nativita" is an international research and production pharmaceutical company for the development and production of innovative medicines for the treatment of cancer, autoimmune and other serious diseases. The company has a research and production complex, which includes microbiological, chemical laboratories, a shop for the production of medicines, departments of pharmaceutical development and registration of medicines in the Department of production and technology development, as well as medical and scientific departments. The total volume of sales of the company's products in 2018 amounted to $17 million, in 2019 it is planned to increase it to $28 million, to master the production of at least seven new drugs.